Refine
Year of publication
Document Type
- Article (49)
- Preprint (5)
- Conference Proceeding (4)
- Review (1)
Has Fulltext
- yes (59)
Is part of the Bibliography
- no (59)
Keywords
- SARS-CoV-2 (6)
- COVID-19 (5)
- Medizinstudenten (4)
- PCR (4)
- medical students (4)
- ELISA (3)
- antiviral therapy (3)
- occupational infections (3)
- Blutübertragbare Virusinfektionen (2)
- IFT (2)
- Immunenzymtechniken (2)
- Immunoenzyme Techniques (2)
- Impfraten (2)
- Labordiagnostik (2)
- Nadelstichverletzungen (2)
- PRNT (2)
- Virussicherheit (2)
- antiviral drugs (2)
- blood borne infection (2)
- bloodborne viruses (2)
- blutübertragbare Infektionskrankheiten (2)
- needlestick injury (2)
- vaccine uptake rates (2)
- Acute HIV infection (1)
- Ag-RDT (1)
- Akkreditierung (1)
- Anti-CMV IgG (1)
- Antigene Virale/Immunologie (1)
- Antigennachweis (1)
- Antigens,Viral/immunology (1)
- Atherosklerose (1)
- Automatisation (1)
- Autopsy (1)
- BNT162b2 (1)
- Bio safety (1)
- Blut- und Plasmaprodukte (1)
- Bovine Spongiforme Enzephalopathie (BSE) (1)
- Bovine spongiform, encephalopathy (BSE) (1)
- CMVepidemiology (1)
- Cell culture (1)
- ChAdOx1-S (1)
- Chlamydia-Infections/urine (1)
- Chlamydien (1)
- Chlamydieninfektionen/Urin (1)
- Congenital CMVinfection (1)
- Corona virus (1)
- Cytomegalie-Virus (1)
- Cytomegalovirus (1)
- Cytomegalovirus (CMV) (1)
- DIN EN ISO 15189 (1)
- Diagnose (1)
- Diagnosis (1)
- Diagnostik (1)
- Donor screening (1)
- EN ISO 15189 (1)
- Ebola (1)
- Epidemiologie (1)
- Erregernachweis (1)
- Genamplifikation (1)
- Gene-Amplification (1)
- Germany (1)
- HHV-8 (1)
- HIV (1)
- HSV (1)
- HSV type specific antibodies (1)
- HSV-1 (1)
- HSV-2 (1)
- HSV-typenspezifische Antikörper (1)
- Health care workers (1)
- Healthcare worker (1)
- Hepatitis C-Virus (HCV) (1)
- Hepatitis G virus (1)
- Hepatitis G-Virus (1)
- Herpe-Viren (1)
- Herpes Simplex Virus/isolation and purification . (1)
- Herpes simplex Virus/Isolierung und Anreicherung (1)
- Herpes virus (1)
- Heterologous prime-boost (1)
- Human immunodeficiency virus (HIV) (1)
- IFA (1)
- IgG (1)
- Immunogenicity (1)
- Immunosuppression (1)
- Immunsuppression (1)
- Inactivation (1)
- Influenza (1)
- KSHV epidemiology (1)
- KSHV, Epidemiologie (1)
- Koronare Herzkrankheit (1)
- Laborpersonal (1)
- Lack of immunity (1)
- Mandatory Vaccinations (1)
- Medical history (1)
- Mikroneutralisationstest (1)
- Otorhinolaryngological (1)
- POCT (1)
- Pandemic (1)
- Plasmapools (1)
- Plasmapräparate (1)
- Poliomyelitis (1)
- Polioviren (1)
- Polymerase Kettenreaktion (PCR) (1)
- Qualitätsmanagement (1)
- RT-PCR-detection (1)
- Rapid diagnostic test (1)
- Reactogenicity (1)
- ReagentKits, -Diagnostic (1)
- Reagenzkits, Diagnostische (1)
- Respiratorische Infekte (1)
- SARS‐CoV‐2 (1)
- Screening-ELISA (1)
- Sensitivity and Specificity (1)
- Sensitivität und Spezifität (1)
- Seroconverter (1)
- Seroepidemiology (1)
- Serology (1)
- Seroprevalence (1)
- Speziesbarriere (1)
- Stability (1)
- Urethra/Mikrobiologie (1)
- Urethra/microbiology (1)
- Vaccination (1)
- Vaccine uptake rate (1)
- Virological testing (1)
- Virologie (1)
- Virus infection (1)
- Virusinfektionen (1)
- Virusisolierung (1)
- Viruspneumonien (1)
- Vorbeugemaßnahmen (1)
- Western blot (1)
- accreditation (1)
- antibody tests (1)
- antigen detection (1)
- arbeitsbedingte Infektionen (1)
- atherosclerosis (1)
- automation (1)
- behördliche Anforderungen (1)
- blood- and plasma products (1)
- cell culture (1)
- chelator (1)
- chlamydia (1)
- coronary heart disease (1)
- cytomegalovirus (1)
- demonstration of the infectious agent (1)
- diagnostic test (1)
- diagnostics (1)
- drug repurposing (1)
- drug resistance (1)
- eltrombopag (1)
- enteral transmission (1)
- enterale Übertragung (1)
- epidemiology (1)
- healthcare personnel (1)
- healthcare worker (1)
- healthcare workers (1)
- hepatitis C virus (HCV) (1)
- human cytomegalovirus (1)
- human prion diseases (1)
- infant (1)
- infectious diseases (1)
- infectivity (1)
- influenza (1)
- iron chelation (1)
- laboratory diagnostic (1)
- laboratory diagnostics (1)
- laboratory worker (1)
- medizinische Beschäftigte (1)
- medizinisches Personal (1)
- menschliche Prionenerkrarikungen (1)
- microneutralization assay (1)
- monkeypox (1)
- neonate (1)
- neonatology (1)
- neurological impairment (1)
- neutralizing antibodies (1)
- newborn (1)
- newborn screening (1)
- official requirements (1)
- orthopoxvirus (1)
- pertussis (1)
- plasma pools and products (1)
- poliovirus (1)
- polymerase chain reaction (PCR) (1)
- poxvirus (1)
- precautions (1)
- proton pump inhibitors (1)
- quality management (1)
- respiratory infections (1)
- ribavirin (1)
- screening ELISA (1)
- species barrier (1)
- surrogate ELISA (1)
- thrombopietin receptor agonist (1)
- vaccination rates (1)
- viral contamination (1)
- virology (1)
- virus isolation (1)
- virus pneumonia (1)
- virus-safety (1)
Institute
- Medizin (59)
- Georg-Speyer-Haus (1)
Pharmazeutika, die aus humanem Ausgangsmaterialstammen (speziell Blut- und Plasmaprodukte), sind prinzipiell auf ein infektiöses Gefahrenpptential zu prüfen. Dies wurde in den letzten Jahren durch verschiedene Vorfälle auch in das Bewußtsein der Öffentlichkeit gebracht. Durch Blut und Blutprodukte können eine Reihe von Infektionserregern übertragen Werden. Aus virologischer Sicht sind relevant: Humanes Immundefizienz Virus (H^titis B \(irus.(]^ *™-virus B19, Humanes T-Zell-L^I/II, Huhiänes Cj^omegälieyirüs (HCMV).und das;Epstein Barr Virus (EBV). :E)iese Viren weisen sehr un-terschiedliche physikalisch-chemische; Eigenschaften auf, was auf ihre Inaktivierbarkeit einen erbebücheiiEinflußhat. - " , " "Der Gefahreriausschluß hängt iii;-hohem^^ Mäße da-von ab, inwieweit ctie Prödukiiöhsveifahreh in der Lagesind, potentiell vorhandene Viren zu eliminieren oderzu inaktivieren. Daneben soflen die sorgfältige Spendier-auswahl und das Screening gespendeter^ JBlut-Einheitenauf bekannte infektiöse Agenitien:;die Sicherheit einesphannazeutischen Produktes gewährleisten. :Entsprechende Forderungen und Regelungen sinddurch die Europäische Union bereits vor Jähren heraus-gegeben und imletzten Jähr durch bundesdeutsche Be-hörden auf nationaler Ebene in einigen Punkten ergänztbzw. weitergehend präzisiert worden. Dann wird u/a.gefordert, in sogenanntenValidierungsstudien einequain-,titative Abschätzung derGesamtvirusabreichenitigbzyy:-inaktivierung im Verlaufe von mehrstufigen Reini-gungs- und maktivierurigsyerfahren bei der Herstellungsolcher Produkte durchzuführen: Unter Einbeziehungbiometrischer Analysen und durch die Forderung nachKombination mehrerer zur Inaktivierung / Eliminierungvon Viren geeigneter Verfahrensschritte ist sicherzustel-len, daß insgesamt eine Reduktion der Infektiosität um ^[[200~mindestens Falctor l O10 für umhüllte Viren bzw. l O6 fürnicht^umhüllte Viren im Modellsystem gewährleistet unddamit in praxi die Virussicherheit von Blutproduktensichergestellt ist.
Die Einteilung der Pneumonien richtet sich neben klinischen und pathologischen vor allem nach ätiologischen Gesichtspunkten. Es werden diesbezüglich die respirato- bzw. pneumotropen Viren vorgestellt, daneben differentialdiagnostisch wichtige andere Infektionserreger der "Viruspneumonie" (M. pneumoniae, Chlamydia psittaci, Coxiella burnetii) beschrieben und ihre klinischen Aspekte, labordiagnostischen Möglichkeiten sowie die Aussagekraft der verschiedenen Nachweisverfahren diskutiert. Die Letalität der primär virusbedingten Pneumonien ist zwar niedrig, der respiratotrope Virusbefall kann aber Schrittmacher für schwerebakterielle Superinfektionen sein.
Herpes simplex virus type 2 (HSV-2) is the main cause of herpes genitalis, a recurrent sexually transmitted disease. By the use of routine Serologie methods (complement fixation test, enzyme immunoassay), virus carriers are difficult to identify because of strong antibody cross reactions with antigens of HSV-1 which is ubiquitously spread throughout the population. We introduce a microtechnique Western blot system loaded with HSV-1 and HSV-2 type-specific and common antigens on separated nitrocellulose strips. By the simultaneous evaluation of Immunologie reactions with both strips, the occurrence of HSV-2 specific antibodies can be sensitively detected in serum specimens containing antibodies to HSV-1. A total of 158 serum specimens were analyzed and the results obtained by Western blot were compared to those of a screening ELISA and virus isolation performed with smears of herpes lesions.
An agreement of 97.9 % was assessed between Western blot and virus isolation to detect an HSV-1 and HSV-2 infection. Less specific serologic results were produced by the screening ELISA on HSV-2 antibodies which correlated in 85.4 % (41/48) with virus isolation and typing. Concerning HSV-2 antibody testing, Western blot and ELISA showed an overall agreement in 89.8 % of the sera investigated.
As shown by our data, the HSV type specific Western blot proved to be a specific, reproducible and standardized technique. It can be utilized for both sero-epidemiological surveys and determination of the HSV immune status.
Postmortem detection of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) after the exhumation of a corpse can become important, e.g. in the case of subsequent medical malpractice allegations. To date, data on possible detection periods [e.g. by reverse transcription polymerase chain reaction (RT-PCR)] or on the potential infectivity of the virus after an exhumation are rare. In the present study, these parameters were examined in two cases with a time span of approximately 4 months between day of death and exhumation. Using SARS-CoV-2 RT-PCR on swabs of both lungs and the oropharynx detection was possible with cycle threshold (Ct) values of about 30 despite signs of beginning decay. RT-PCR testing of perioral and perinasal swabs and swabs collected from the inside of the body bag, taken to estimate the risk of infection of those involved in the exhumation, was negative. Cell culture-based infectivity testing was negative for both, lung and oropharyngeal swabs. In one case, RT-PCR testing at the day of death of an oropharyngeal swab showed almost identical Ct values as postmortem testing of an oropharyngeal swab, impressively demonstrating the stability of viral RNA in the intact corpse. However, favorable climatic conditions in the grave have to be taken into account, as it was wintertime with constant low temperatures. Nevertheless, it was possible to demonstrate successful postmortem detection of SARS-CoV-2 infection following exhumation even after months in an earth grave.
Background: Europe was certified to be polio-free in 2002 by the WHO. However, wild polioviruses remain endemic in India, Pakistan, Afghanistan, and Nigeria, occasionally causing polio outbreaks, as in Tajikistan in 2010. Therefore, effective surveillance measures and vaccination campaigns remain important. To determine the poliovirus immune status of a German study population, we retrospectively evaluated the seroprevalence of neutralizing antibodies (NA) to the poliovirus types 1, 2 and 3 (PV1, 2, 3) in serum samples collected from 1,632 patients admitted the University Hospital of Frankfurt am Main, Germany, in 2001, 2005 and 2010.
Methods: Testing was done by using a standardized microneutralization assay.
Results: Level of immunity to PV1 ranged between 84.2% (95%CI: 80.3-87.5), 90.4% (88.3-92.3) and 87.5% (85.4-88.8) in 2001, 2005 and 2010. For PV2, we found 90.8% (87.5-90.6), 91.3% (89.3-93.1) and 89.8% (88.7-90.9), in the same period. Seroprevalence to PV3 was 76.6% (72.2-80.6), 69.8% (66.6-72.8) and 72.9% (67.8-77.5) in 2001 and 2005 and 2010, respectively. In 2005 and 2010 significant lower levels of immunity to PV3 in comparison to PV1 and 2 were observed. Since 2001, immunity to PV3 is gradually, but not significantly decreasing.
Conclusion: Immunity to PV3 is insufficient in our cohort. Due to increasing globalization and worldwide tourism, the danger of polio-outbreaks is not averted - even not in developed countries, such as Germany. Therefore, vaccination remains necessary.
Einleitung: Medizinisches Personal ist dem Risiko ausgesetzt, sich an kontaminierten Instrumenten zu verletzen. Nadelstichverletzungen (NSV) können zu ernsthaften und möglicherweise schwerwiegenden Infektionen wie Hepatitis B (HBV), Hepatitis C (HCV) und HIV-Infektionen führen. Dieses Risiko betrifft auch Medizinstudenten im Verlaufe ihrer klinischen Ausbildung. Jede NSV sollte als Arbeitsunfall gemeldet werden, damit postexpositionelle Maßnahmen eingeleitet sowie etwaige Infektionen frühzeitzeitig erkannt und behandelt werden können. Im Falle einer Infektion können versicherungsrechtliche Ansprüche gegenüber den Berufsgenossenschaften geltend gemacht werden. Ziel unserer Studie war die Erhebung der Häufigkeit und Melderate von NSV bei Medizinstudenten.
Methoden: Anonyme Fragebogenerhebung bei Medizinstudenten vor Beginn des Praktischen Jahres.
Ergebnisse: Von den befragten Studenten gaben 58,8% (n=183/311) mindestens eine NSV im Rahmen des Studiums an. Insgesamt 284 NSV wurden von den befragten Studenten gemeldet. Lediglich 38,3% der Studenten hatten alle NSV gemeldet. Die häufigste Ursache für das Nichtmelden der NSV war Schamgefühl aufgrund der Verletzung (54,0%).
Schlussfolgerungen: Expositionen gegenüber Blut sind eine häufige und ernstzunehmende Gefährdung von Medizinstudenten. Es sollten Maßnahmen ergriffen werden, um die Häufigkeit von NSV zu reduzieren und das Meldeverhalten der Studenten zu optimieren. Entsprechende Schulungen sollten sowohl die technischen Fertigkeiten der Studenten als auch das Bewusstsein über die Gefährdung durch NSV vermitteln.
In resource-limited or point-of-care settings, rapid diagnostic tests (RDTs), that aim to simultaneously detect HIV antibodies and p24 capsid (p24CA) antigen with high sensitivity, can pose important alternatives to screen for early infections. We evaluated the performance of the antibody and antigen components of the old and novel version of the Determine™ HIV-1/2 Ag/Ab Combo RDTs in parallel to quantifications in a fourth-generation antigen/antibody immunoassay (4G-EIA), p24CA antigen immunoassay (p24CA-EIA), immunoblots, and nucleic acid quantification. We included plasma samples of acute, treatment-naïve HIV-1 infections (Fiebig stages I–VI, subtypes A1, B, C, F, CRF02_AG, CRF02_AE, URF) or chronic HIV-1 and HIV-2 infections. The tests’ antigen component was evaluated also for a panel of subtype B HIV-1 transmitted/founder (T/F) viruses, HIV-2 strains and HIV-2 primary isolates. Furthermore, we assessed the analytical sensitivity of the RDTs to detect p24CA using a highly purified HIV-1NL4-3 p24CA standard. We found that 77% of plasma samples from acutely infected, immunoblot-negative HIV-1 patients in Fiebig stages II–III were identified by the new RDT, while only 25% scored positive in the old RDT. Both RDTs reacted to all samples from chronically HIV-1-infected and acutely HIV-1-infected patients with positive immunoblots. All specimens from chronically infected HIV-2 patients scored positive in the new RDT. Of note, the sensitivity of the RDTs to detect recombinant p24CA from a subtype B virus ranged between 50 and 200 pg/mL, mirrored also by the detection of HIV-1 T/F viruses only at antigen concentrations tenfold higher than suggested by the manufacturer. The RTD failed to recognize any of the HIV-2 viruses tested. Our results indicate that the new version of the Determine™ HIV-1/2 Ag/Ab Combo displays an increased sensitivity to detect HIV-1 p24CA-positive, immunoblot-negative plasma samples compared to the precursor version. The sensitivity of 4G-EIA and p24CA-EIA to detect the major structural HIV antigen, and thus to diagnose acute infections prior to seroconversion, is still superior.
As the current SARS-CoV-2 pandemic continues, serological assays are urgently needed for rapid diagnosis, contact tracing and for epidemiological studies. So far, there is little data on how commercially available tests perform with real patient samples and if detected IgG antibodies provide protective immunity. Focusing on IgG antibodies, we demonstrate the performance of two ELISA assays (Euroimmun SARS-CoV-2 IgG & Vircell COVID-19 ELISA IgG) in comparison to one lateral flow assay ((LFA) FaStep COVID-19 IgG/IgM Rapid Test Device) and two in-house developed assays (immunofluorescence assay (IFA) and plaque reduction neutralization test (PRNT)). We tested follow up serum/plasma samples of individuals PCR-diagnosed with COVID-19. Most of the SARS-CoV-2 samples were from individuals with moderate to severe clinical course, who required an in-patient hospital stay.
For all examined assays, the sensitivity ranged from 58.8 to 76.5% for the early phase of infection (days 5-9) and from 93.8 to 100% for the later period (days 10-18) after PCR-diagnosed with COVID-19. With exception of one sample, all positive tested samples in the analysed cohort, using the commercially available assays examined (including the in-house developed IFA), demonstrated neutralizing (protective) properties in the PRNT, indicating a potential protective immunity to SARS-CoV-2. Regarding specificity, there was evidence that samples of endemic coronavirus (HCoV-OC43, HCoV-229E) and Epstein Barr virus (EBV) infected individuals cross-reacted in the ELISA assays and IFA, in one case generating a false positive result (may giving a false sense of security). This need to be further investigated.
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) serological assays are urgently needed for rapid diagnosis, contact tracing, and for epidemiological studies. So far, there is limited data on how commercially available tests perform with real patient samples, and if positive tested samples show neutralizing abilities. Focusing on IgG antibodies, we demonstrate the performance of two enzyme‐linked immunosorbent assay (ELISA) assays (Euroimmun SARS‐CoV‐2 IgG and Vircell COVID‐19 ELISA IgG) in comparison to one lateral flow assay (FaStep COVID‐19 IgG/IgM Rapid Test Device) and two in‐house developed assays (immunofluorescence assay [IFA] and plaque reduction neutralization test [PRNT]). We tested follow up serum/plasma samples of individuals polymerase chain reaction‐diagnosed with COVID‐19. Most of the SARS‐CoV‐2 samples were from individuals with moderate to the severe clinical course, who required an in‐patient hospital stay. For all examined assays, the sensitivity ranged from 58.8 to 76.5% for the early phase of infection (days 5‐9) and from 93.8% to 100% for the later period (days 10‐18).
Characterization of neonates born to mothers with SARS-CoV-2 infection: review and meta-analysis
(2020)
Characterization of neonates born to mothers with SARS-CoV-2 infection has been partially carried out. There has been no systematic review providing a holistic neonatal presentation including possible vertical transmission. A systematic literature search was performed using PubMed, Google Scholar and Web of Science up to June, 6 2020. Studies on neonates born to mothers with SARS-CoV-2 infection were included. A binary random effect model was used for prevalence and 95% confidence interval. 32 studies involving 261 neonates were included in meta-analysis. Most neonates born to infected mothers did not show any clinical abnormalities (80.4%). Clinical features were dyspnea in 11 (42.3%) and fever in 9 newborns (19.1%). Of 261 neonates, 120 neonates were tested for infection, of whom 12 (10.0%) tested positive. Swabs from placenta, cord blood and vaginal secretion were negative. Neonates are mostly non affected by the mother's SARS-CoV-2 infection. The risk of vertical transmission is low.